- B Cells
- Gene Expression
Regulation of B cell transcription and development Lymphocyte differentiation proceeds through multiple stages characterized by the expression of distinct sets of genes. My laboratory’s goals include understanding how the nuclear proteins Early B cell Factor (EBF) and Pax5 (B cell-specific activator protein) regulate B lineage specification, commitment and the immune response to antigens. EBF has been identified as a crucial factor for lineage determination. EBF regulates many genes (such as mb-1) involved in assembly of the pre-B and mature B cell receptors for antigen (pre-BCR and BCR). We recently identified EBF as an early mediator of changes in mb-1 gene chromatin structure, including DNA demethylation and enhanced accessibility. Pax5 acts downstream of EBF as an important regulator of the early B cell-specific transcriptome, but is also important at later stages of B cell maturation. Notably, Pax5 is a key factor for establishing B cell lineage commitment. To better understand how these proteins function in B cells, my lab employs a combination of biochemical and genetic methods, including transgenic and gene targeted mice. Ultimately, we wish to understand how regulatory signals are integrated for activation and/or repression of genes that contribute to normal immunity, immune diseases, and cancer.
||University of Washington, Seattle, PhD, Microbiology
||University of Washington, Seattle, MS, Microbiology
||University of California, Berkeley, BA, Genetics
||Howard Hughes Medical Institute, Postdoctoral
||University of California, San Francisco, Postdoctoral
Awards & Recognition
2009-2013: Member, NIH CMI-B Study Section
2006-2011: Editorial Board, Journal of Biological Chemistry
2008-Present: Advisory Board, Faculty of 1000 Biology
2008: Ad hoc Member, NIH Special Emphasis Panel/Scientific Review Group ZRG1 IMM-J (02)
2007: Research Award, Rocky Mountain Chapter of the Arthritis Foundation
2007: Co-editor, Current Opinion in Immunology, Lymphocyte Development 2000-2001,
2006-2007: Scientific Advisory Board Member, Cancer League of Colorado
2005: Outstanding Scientific Achievement Award, National Jewish Health
1997-2005: Ad hoc Member, NIH Special Emphasis Panel ZRG IMB 01
1997-2001: Peer Review Committee on Development, Differentiation and Cancer, Regular Member, American Cancer Society
1997: Harmon Foundation Award for Arthritis Research
7/1990-6/1993: Fellow of the Leukemia Society of America
The Epigenetics Society
American Society for Biochemistry and Molecular Biology
Member, American Society of Microbiology
Member, American Association of Immunologists
Member, American Association for Cancer Research
Lukin, K, S Fields, L Guerrettaz, D Straign, V Rodriguez, S Zandi, R Månsson, JC Cambier, M Sigvardsson and J Hagman. 2011. A dose-dependent role for EBF1 in repressing non-B cell specific genes. Eur J Immunol, 41:1787-1793 (PMCID: PMC3127254).
Musselman, CA, J Ramirez, JK Sims, RE Mansfield, SS Oliver, JM Denu, JP Mackay, PA Wade, J Hagman and TG Kutateladze. 2012. Bivalent recognition of nucleosomes by the tandem PHD fingers of CHD4 is required for CHD4-mediated repression. Proc Natl Acad Sci USA, 109:787-792 (PMCID: PMC3271909).
Hagman, J, J Ramírez and K Lukin. 2012. B lymphocyte lineage specification, commitment and epigenetic control of transcription by Early B cell Factor 1. Curr Topics Micro Immunol, 356:17-38 (PMID: 21735360).
Dege, C, and J Hagman. 2012. Activation of Aicda gene transcription by Pax5 in plasmacytoma cells. Immunol Res, [Epub ahead of print] (PMID: 22956488).
Ramirez, J, C Dege, KG Kutateladze and J Hagman. 2012. MBD2 and multiple domains of CHD4 are required for transcriptional repression by Mi-2/NuRD complexes. Mol Cell Biol, [Epub ahead of print] (PMID: 23071088).
Conflicts of Interest
National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice
and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management
plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians
or scientists. View this faculty member’s industry relationships and collaborations.
Ask a Question through Patient Portal
to your My National Jewish Health
patient portal account to communicate with your care team, manage appointments, and more. Create an Account
National Jewish Health Main Campus
1400 Jackson St.
Denver, CO 80206
The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes.
Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey